API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

China API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir, Find details about China Favipiravir, Favipiravir Powder from API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

Basic Info.

Model NO.

Condavo-Favipiravir

Name

Favipiravir

Product Name

Favipiravir Powder

Appearance

White Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

COA

Available

CAS

259793-96-9

C5h4fn3o2

157.1025632

Density

1.78

Melting Point

187CTO 193c

Boiling Point

552.6c at 760 Mmhg

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Model NO.

Condavo-Favipiravir

Name

Favipiravir

Product Name

Favipiravir Powder

Appearance

White Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

COA

Available

CAS

259793-96-9

C5h4fn3o2

157.1025632

Density

1.78

Melting Point

187CTO 193c

Boiling Point

552.6c at 760 Mmhg

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Product Desciption

API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

Product Name	Favipiravir
CAS	259793-96-9
Appearance	White crystalline powder
MF	C5H4FN3O2
MW	157.1025632
Purity	99%
Shelf Life	2 Years

Favipiravir (T-705) is related to the selective inhibition of viral RNA polymerase. It acts by competing with purine nucleosides and disrupts viral replication in the RNA virus. This, hence explains its potential in inhibiting the RNA -dependent RNA polymerase of many RNA viruses. Some studies also suggest that favipiravir induces RNA mutations which results to a non-viable viral phenotype. It should be noted that most antiviral drugs require early use in order to effectively control the rate of viral replication. This is because, viral replication can slow down in the later stages of the disease resulting to other issues as the body's immune system responds rapidly and could lead to organ failure. Favipiravir (T-705) is selective and hence does not block RNA or DNA synthesis in the cells of mammals and also its non-toxic to them.

API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir As a new broad-spectrum anti RNA virus drug, favipiravir was approved for marketing in Japan in March 2014 and used for antiviral treatment of influenza A and B. In addition to the influenza virus, the drug also showed good antiviral activity to a variety of RNA viruses, such as sand virus, Bunia virus, rabies virus, etc.
API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir

Fapilavir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza viruses, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus, rabies virus, etc.

API Anti-Virus Favipiravir 99% Purity Favipiravir Powder Favipiravir